FDA starts calling AI 'Super Intelligence' in new documents, with no new rules for sponsors
The FDA said that from November 16 it will use 'Super Intelligence' and 'SI' in place of 'artificial intelligence' in new public documents, as Executive Order 14434 directs. Review standards and sponsor obligations do not change.
Docket, covering health regulation and AI in care
, 3 min read
Nov 16date FDA began using 'SI' in new documents
What to know
- FDA will use 'Super Intelligence' and 'SI' in newly issued public documents and communications from November 16, 2026.
- Existing guidance, regulations and Federal Register notices stay in effect as written and change only at their next substantive revision.
- FDA says the order creates no new requirement for sponsors, applicants or manufacturers.
The Food and Drug Administration (FDA) said it began using "Super Intelligence" and "SI" in place of "artificial intelligence" and "AI" in newly issued public documents and communications on November 16, 2026. The agency posted a notice explaining the change, which carries out Executive Order 14434, "Inaugurating the Era of Super Intelligence." The order was signed on September 29 and published in the Federal Register on October 2.
The change is a matter of wording. The FDA says it creates no new obligations for the companies that submit products for review, and it does not change how AI-enabled medical devices are cleared or approved. Citeline's Pink Sheet reported the notice the same day, under a headline saying sponsors can still use "AI".
What changes at FDA
According to the notice, new public-facing FDA documents will use the new terms where they apply and the law allows. Forms, electronic submission templates, databases and web pages will be updated on the agency's normal maintenance cycles rather than all at once. Pink Sheet reported that the FDA eventually will update all forms and templates with the revised term.
Older documents are left alone. Guidance, regulations, Federal Register notices and other documents the FDA has already issued remain in effect as written. The agency will switch their wording only when it next makes a substantive revision to each one. That covers guidance central to AI-enabled devices, such as the agency's guidance on predetermined change control plans.
Where a statute or regulation uses "artificial intelligence" or "AI", the FDA will keep quoting and citing those words as written.
What does not change for companies
The FDA notice says the order "does not create any new requirement" for sponsors, applicants, manufacturers or others who submit information to the agency. That includes product labeling, established names, proprietary names and trade names. A company describing its product as AI-enabled does not have to rename anything.
The order itself defines Super Intelligence as the technologies already covered by the federal definition of artificial intelligence in 15 U.S.C. 9401(3). So the set of software the FDA regulates is the same. The review pathways, from 510(k) clearance to De Novo and premarket approval (see our explainer on clearance, approval and De Novo), are not altered by the order.
The wider federal switch
Executive Order 14434 tells federal agencies, to the maximum extent permitted by law, to use the new terms in correspondence, public communications, websites, reports and policy documents. It does not require agencies to rewrite previously issued regulations, contracts or grants, and it says it creates no enforceable rights.
Other agencies have already adopted the language. The Centers for Medicare & Medicaid Services titled its recent roadmap for AI in clinical care a Clinical Super Intelligence roadmap, and the Justice Department named its new unit the Super Intelligence Task Force.
The order also gives the President's science and technology adviser 60 days from signing, which falls in late November, to send the President proposed legislative language for a federal definition of Super Intelligence, including any change to the statutory AI definition. Only Congress can change that statute.
Why it matters
For device makers and digital health companies, the practical effect is a new word on FDA web pages, forms and future guidance, not new rules: submissions, labels and review standards stay as they were. The part to watch is the proposed statutory definition due to the President, since a change Congress passes to the legal meaning of AI could affect which software falls under federal programs.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- FDA's Use of "Super Intelligence" and "SI" Under Executive Order 14434, US Food and Drug Administration, November 16, 2026
- Sponsors Will See 'Super Intelligence' On US FDA Forms, Webpages Soon, But Using 'AI' Still OK, Citeline Pink Sheet, November 16, 2026
- Executive Order 14434: Inaugurating the Era of Super Intelligence, The American Presidency Project, September 29, 2026
FDA and health regulationAI law and policyDigital health and AI in care
Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.